|
Abetalipoproteinemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Numbers of NPM-ALK transcripts were normalized to 10(4) copies ABL (NCNs).
|
17392503 |
2007 |
|
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
Acute Erythroblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using cell line-based assays, the secretion of erythroblastic leukemia viral oncogene homologue (ERBB) ligands has been reported to contribute to resistance against crizotinib in lung cancer with the echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase fusion gene.
|
25695223 |
2015 |
|
Acute leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The NK lymphoma with acute leukemia had a t(2;5) but was CD30- and anaplastic lymphoma kinase negative.
|
11488062 |
2001 |
|
Acute lymphocytic leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Cytogenetic characteristics of pediatric NHL include 14q11.2 rearrangements in T-cell lymphoblastic leukemia/lymphomas (LBL), ALK rearrangements in anaplastic large cell lymphomas (ALCL), and CMYC translocations in both Burkitt and Burkitt-like lymphomas (BL/BLL).
|
16127683 |
2005 |
|
Acute myelomonocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report a case of acute myelomonocytic leukemia in a 31-year-old woman with an unusual rearrangement between RAN-binding protein 2 (RANBP2) and ALK and a karyotype of 45,XX,inv(2)(p23q21),-7[20].
|
24613277 |
2014 |
|
Acute Promyelocytic Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Instead, phosphoproteomics and confirmatory functional studies revealed that the STAT1 overactivation is the key mechanism of ALK-TKI addiction in ALCL.
|
31804622 |
2020 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Medical management did not improve outcomes, except for two ALK receptor tyrosine kinase (ALK)-rearranged adenocarcinomas that responded to ALK inhibitor therapy alone.
|
30194036 |
2018 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
|
22569898 |
2012 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Changes in the epidermal growth factor receptor (<i>EGFR</i>) gene, Kirsten rat sarcoma viral oncogene (<i>KRAS</i>), v-Raf murine sarcoma viral oncogene homolog B (<i>BRAF</i>), gene encoding neurofibromin (<i>NF1</i>), anaplastic lymphoma kinase (<i>ALK</i>) and <i>ROS1</i> are the main genes that suffer alterations in the tumors of patients with ADC.
|
28840016 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
ALK abnormalities were observed in six AD (7.5%; 6/80) and in single patients with adenosuqamous lung carcinoma.
|
27879019 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A 60-year-old Korean man had a lung mass which was a poorly differentiated adenocarcinoma with ALK overexpression.
|
24736082 |
2014 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although negative for epidermal growth factor receptor mutations, ALK rearrangements were detected in adenocarcinoma and spindle-cell components.
|
29310482 |
2018 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Previous studies have revealed that EGFR mutation and/or EML4-ALK gene fusion rate was higher in the non-smoker Asian females with pulmonary adenocarcinoma.
|
22707299 |
2012 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, a major issue of current research is to define the morphological and immunophenotypic features of lung ALK-rearranged adenocarcinomas to improve the selection of tumors suitable for molecular genotyping.
|
28364271 |
2017 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Meta-analysis demonstrated that EML4-ALK translocation occurred in 4.84% (125/2580) of unselected patients with NSCLC, and was also predominant in non-smoking patients with adenocarcinoma.
|
23341890 |
2013 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
She was diagnosed with ALK rearrangement-positive adenocarcinoma by histopathology of the primary tumor.
|
30900377 |
2019 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aim of our study was to assess EGFR-mutations and ALK-rearrangements in different intratumor subtypes and/or growth patterns in a series of mixed adenocarcinomas and adenosquamous carcinomas.
|
26422230 |
2015 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
EML4-ALK adenocarcinomas constitute a new molecular subgroup of lung tumours that respond very well to crizotinib, an ALK inhibitor.
|
22153831 |
2012 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Primary SRC of the lung is a rare subtype of adenocarcinoma, carries a worse prognosis when compared to adenocarcinoma and shares many of the recently identified clinicopathologic characteristics ascribed to EML4-ALK positive non-small cell lung cancer.
|
20130484 |
2010 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Epidermal growth factor receptor mutations, KRAS gene mutations, and anaplastic lymphoma kinase gene alterations were statistically prevalent in papillary-predominant (P = 0.00001), invasive mucinous (P = 0.00001), and micropapillary- and acinar-predominant (P = 0.00001) adenocarcinomas, respectively.
|
23891509 |
2013 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We selected combined neuroendocrine differentiation in pulmonary adenocarcinoma cases with positive ALK immunostaining.
|
29629521 |
2018 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ALK mutations have been identified in approximately 2.4-13% of patients with NSCLC, occurring more frequently in adenocarcinomas and never and light smokers.
|
21844131 |
2012 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
ALK fusions were positively associated with a micropapillary pattern (P = .002) and were negatively associated with a lepidic pattern (P = .008) in an expanded statistical analysis of 900 individual adenocarcinoma components, although they appeared to be more common in acinar-predominant LADCs in the analysis of 629 patients.
|
26416997 |
2015 |